Celgene Corporation to Present at Investor Conferences in September
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (CELG) announced its presentations at four upcoming investor conferences will be webcast live and will be available in the investor relations section of the Companys Web site at www.celgene.com. Celgene management will provide an overview of the Company.
- Thursday, September 6, 2012 Celgene will present at the Stifel Nicolaus Healthcare Conference at 9:10 a.m. ET.
- Wednesday, September 12, 2012 Celgene will present at the Morgan Stanley Healthcare Conference at 8:35 a.m. ET.
- Thursday, September 13, 2012 Celgene will present at the Bank of America Merrill Lynch Global Healthcare Conference in London at 5:35 a.m. ET.
- Wednesday, September 19, 2012 Celgene will present at the UBS Global Life Sciences Conference at 3:00 p.m. ET.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the companys Web site at www.celgene.com.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," outlook and similar expressions. Forward-looking statements are based on managements current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
Jacqualyn A. Fouse, Ph.D., EVP, Chief Financial Officer, 908-673-9956
Patrick E. Flanigan III, VP, Investor Relations, 908-673-9969
Source: Celgene CorporationCopyright Business Wire 2012